Back

EPA:DHA 6:1 prevents right ventricular dysfunction and lung vascular remodeling in monocrotaline-induced pulmonary arterial hypertension in rats by mitigating inflammatory and pro-oxidant responses

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Cardiac remodeling across the ejection fraction spectrum Ventricular Remodelling HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Said AMISSI

University of Strasbourg, Strasbourg (France)

4 More presentations in this session

Presentation thumbnail
Left ventricular reverse remodeling in heart failure with reduced ejection fraction: determinants and outcomes in a multidisciplinary heart failure clinic in a resource limited setting
Doctor B. Chung (Kuching, MY)
Abstract Slides Video
Presentation thumbnail
Echocardiographic parameters in patients with right heart failure and sarcopenia.
Doctor M. Hernandez Hernandez (Mexico City, MX)
Abstract Slides Video
Presentation thumbnail
Cardiac reverse remodeling after SGLT2 inhibitor therapy: exploring beyond sex differences
Doctor S. Prosperi (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Multiparametric approach to predict long-term survival in ischemic heart failure patients undergoing surgical ventricular reconstruction
Doctor G. Guida (San Donato Milanese, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac remodeling across the ejection fraction spectrum

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Circulating low-grade inflammation in human pulmonary arterial hypertension promotes eNOS-NO/ROS imbalance: Involvement of the angiotensin and the endothelin pathways and prevention by EPA:DHA 6:1
thumbnail
Congress Presentation
Pathobiological characterization of pulmonary hypertension associated with heart failure with preserved ejection fraction
thumbnail
Congress Presentation
Effects of BET Inhibition on lung micro-environmental changes in obesity-related pulmonary Arterial Hypertension (PAH)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources